Effects of treatment with metformin on TSH levels: A meta-analysis of literature studies

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages

  Lupoli, Roberta ^a   Di Minno, Alessandro ^a   Tortora, Anna ^a   Ambrosino, Pasquale ^a   Lupoli, Gelsy Arianna ^a   Di Minno, Matteo Nicola Dario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; METFORMIN; THYROTROPIN;

ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DRUG EFFECT; EUTHYROIDISM; HUMAN; HYPOTHYROIDISM; META ANALYSIS; PRIORITY JOURNAL; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME;

HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTHYROIDISM; METFORMIN; THYROTROPIN; THYROXINE;

EID: 84892178287     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2965     Document Type: Article

References (24)

1. Chubb SA, Davis WA, Inman Z, Davis TM. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Freemantle diabetes study. Clin Endocrinol (Oxf). 2005; 62:480-486.
2. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:71-30.
3. Andújar-Plata P, Pi-Sunyer X, Laferrere B. Metformin effects revisited. Diabetes Res Clin Pract. 2012;95:1-9.
4. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-1174.
5. Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol. 2010;205:97-106.
6. Nelson LE, Valentine RJ, Cacicedo JM, Gauthier MS, Ido Y, Ruderman NB. A novel inverse relationship between metformin-trig gered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed Hep G2 cells. Am J Physiol Cell Physiol. 2012;303: C4-C13.
7. Abdulrahman R, Boon MR, Sips HC, et al. Impact of metformin and compound C on NIS expression and iodine uptake in vitro and in vivo: a role for CRE in AMPK modulation of thyroid function [published online September 25, 2013]. Thyroid. doi:10.1089/ thy.2013.0041.
8. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-1060.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
10. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in metaanalysis. BMJ. 2001;323:101-105.
11. Altman DG, Bland JM. Detecting skewness from summary information. BMJ. 1996;313:1200.
12. Isidro ML, Penín MA, Nemiña R, Cordido F. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine. 2007;32:79-82.
13. Cappelli C, Rotondi M, Pirola I, et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care. 2009;32:1589-1590.
14. Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res. 2011;8:47-48.
15. Cappelli C, Rotondi M, Pirola I, et al. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol. 2012;167:261-265.
16. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006;91:225-227.
17. Krysiak, R., Okopien, B. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol (Oxf). 2011;75:404-406.
18. López M, Varela L, Vázquez MJ, et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med. 2010;16:1001-1008.
19. Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord. 2011;9:69-75.
20. Oleandri SE, Maccario M, Rossetto R, et al. Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. J Endocrinol Invest. 1999;22:134-140.
21. Fox CS, Pencina MJ, D'Agostino RB, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med. 2008;168:587-592.
22. Rotondi M, Cappelli C, Magri F, et al. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2011;75:378-381.
23. Díez JJ, Iglesias P. Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol (Oxf). 2013;78:505-511.
24. Kitahara CM, Platz EA, Ladenson PW, Mondul AM, Menke A, Berrington de González A. Body fatness and markers of thyroid function among U.S. men and women. PLoS One. 2012;7:e34979.